Reproductive Endocrinology — MCQs

Reproductive Endocrinology Indian Medical PG Practice Questions and MCQs

Question 71: The maturation index on vaginal cytology is a diagnostic method for evaluating the endocrine status of:

A. Ovary
B. Uterus
C. Cervix
D. Vagina (Correct Answer)

Explanation: **Explanation:** The **Maturation Index (MI)** is a clinical tool used to assess the hormonal status of a patient by examining the proportions of three types of cells found in the **vaginal epithelium**: Parabasal, Intermediate, and Superficial cells. **Why Vagina is the correct answer:** The vaginal squamous epithelium is highly sensitive to circulating sex steroids. **Estrogen** promotes the maturation of the epithelium into superficial cells, while **Progesterone** (and androgens) leads to the predominance of intermediate cells. In the absence of these hormones (e.g., prepuberty or menopause), the epithelium remains thin, consisting primarily of parabasal cells. By calculating the ratio (e.g., 0/40/60), clinicians can directly evaluate the endocrine effect on the **vaginal wall**. **Why other options are incorrect:** * **Ovary:** While the MI reflects ovarian function (estrogen/progesterone production), the cytology is performed on cells exfoliated from the vagina, not the ovary itself. * **Uterus:** The uterine lining (endometrium) responds to hormones via histological changes (proliferative vs. secretory phases), but MI specifically utilizes squamous cells from the vaginal vault. * **Cervix:** Although the ectocervix has squamous epithelium, the standard site for MI is the **lateral vaginal wall** (upper third) to avoid contamination with cervical inflammatory cells or mucus. **High-Yield Clinical Pearls for NEET-PG:** * **Shift to the Left:** Predominance of Parabasal cells (seen in Menopause/Atrophic vaginitis). * **Shift to the Right:** Predominance of Superficial cells (seen in high Estrogen states or mid-cycle). * **Mid-zone Shift:** Predominance of Intermediate cells (seen in Pregnancy or Luteal phase). * **Fern Test:** Another bedside test; positive (ferning) indicates Estrogen, negative (beading) indicates Progesterone.

Question 72: All the following are included in the Rotterdam criteria for Polycystic Ovarian Syndrome (PCOS) diagnosis except?

A. Hyperandrogenism
B. Amenorrhea or oligomenorrhea
C. Polycystic ovaries by ultrasound
D. Weight of the patient (Correct Answer)

Explanation: The **Rotterdam Criteria (2003)** is the gold standard for diagnosing Polycystic Ovarian Syndrome (PCOS). To make a diagnosis, at least **two out of the three** following criteria must be present, provided other etiologies (like CAH or Cushing’s) are excluded: 1. **Hyperandrogenism (Option A):** This can be clinical (hirsutism, acne, male-pattern alopecia) or biochemical (elevated serum testosterone/androstenedione). 2. **Oligomenorrhea or Amenorrhea (Option B):** This represents ovulatory dysfunction. Patients typically have <9 menses per year. 3. **Polycystic Ovaries on Ultrasound (Option C):** Defined as ≥12 follicles (2–9 mm diameter) in either ovary or an increased ovarian volume (>10 cm³). *Note: Updated international guidelines now suggest a threshold of ≥20 follicles if using high-frequency transvaginal probes.* **Why Option D is the correct answer:** While **obesity** and increased weight are frequently associated with PCOS (seen in ~50–70% of cases) and exacerbate insulin resistance, **weight is not a diagnostic criterion**. A patient can be "Lean PCOS" and still meet the Rotterdam criteria. **High-Yield Clinical Pearls for NEET-PG:** * **LH:FSH Ratio:** Classically 3:1, but no longer used for primary diagnosis. * **Gold Standard Investigation:** Transvaginal Ultrasound (TVS). * **Treatment of Choice:** * Infertility: **Letrozole** (First line) > Clomiphene Citrate. * Hirsutism/Irregular cycles: Combined Oral Contraceptive Pills (COCPs). * Metabolic issues: Lifestyle modification and Weight loss (most important initial step). * **AMH Levels:** Often significantly elevated in PCOS due to the high number of pre-antral follicles.

Question 73: What are the causes of female pseudohermaphroditism?

A. 17-alpha hydroxylase deficiency
B. 21-alpha hydroxylase deficiency (Correct Answer)
C. Mixed gonadal dysgenesis
D. All of the above

Explanation: **Explanation:** **Female Pseudohermaphroditism** (now termed 46,XX Disorder of Sex Development) refers to individuals with a 46,XX karyotype and normal ovaries, but whose external genitalia are virilized due to excessive androgen exposure in utero. **Why Option B is Correct:** **21-alpha hydroxylase deficiency** is the most common cause of **Congenital Adrenal Hyperplasia (CAH)**, accounting for over 90% of cases. In this condition, a block in the cortisol synthesis pathway leads to an accumulation of precursors (like 17-OH progesterone), which are shunted into the androgen pathway. The resulting high levels of testosterone cause virilization of the female fetus (ambiguous genitalia, clitoromegaly), making it the classic cause of female pseudohermaphroditism. **Why Other Options are Incorrect:** * **Option A (17-alpha hydroxylase deficiency):** This enzyme is required for the production of both cortisol and sex hormones. Deficiency leads to a **lack of androgens**, resulting in sexual infantilism in females and **male pseudohermaphroditism** (undervirilization) in males. * **Option C (Mixed Gonadal Dysgenesis):** This is a chromosomal disorder (typically 45,X/46,XY mosaicism) characterized by a streak gonad on one side and a testis on the other. It is not a cause of female pseudohermaphroditism, as the karyotype is not 46,XX. **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause of ambiguous genitalia** in a newborn: CAH (21-hydroxylase deficiency). * **Biochemical Marker:** Elevated **17-hydroxyprogesterone (17-OHP)**. * **Clinical Presentation:** Salt-wasting crisis (hyponatremia, hyperkalemia, hypotension) occurs in 75% of cases due to aldosterone deficiency. * **Maternal causes:** Androgen-secreting tumors (Luteoma of pregnancy) or intake of progestogens/androgens during pregnancy can also cause female pseudohermaphroditism.

Question 74: For hormonal study, which wall of the vagina should the sample be taken from?

A. Anterior wall
B. Posterior wall
C. Lateral wall (Correct Answer)
D. Any wall

Explanation: **Explanation:** In gynecological practice, hormonal evaluation via vaginal cytology (often referred to as a **Maturation Index**) relies on the assessment of squamous epithelial cells. The correct site for sampling is the **upper third of the lateral vaginal wall**. **Why the Lateral Wall?** The lateral vaginal wall is the most sensitive to hormonal fluctuations (estrogen and progesterone) because it is less affected by external factors. Estrogen promotes the maturation of the epithelium into superficial cells, while progesterone leads to an increase in intermediate cells. Sampling from this specific site provides a "clean" hormonal profile, as it is relatively protected from inflammatory changes and mechanical irritation. **Why other options are incorrect:** * **Anterior Wall:** This area is frequently subject to mechanical friction and is in close proximity to the urethra, which can lead to contamination with inflammatory cells or urinary sediment, skewing the hormonal interpretation. * **Posterior Wall:** This site is the primary reservoir for the **vaginal pool**. Samples taken here often contain debris, inflammatory exudate, and degenerating cells from the cervix or uterus, making it unsuitable for accurate hormonal cytological assessment. * **Any Wall:** Hormonal assessment requires standardization. Using "any wall" would lead to inconsistent results due to the varying degrees of inflammation and debris found in different vaginal fornices. **High-Yield NEET-PG Pearls:** * **Maturation Index (MI):** Expressed as a ratio of **Parabasal : Intermediate : Superficial** cells. * **Estrogen Effect:** Causes a "shift to the right" (increase in superficial cells). * **Progesterone Effect:** Causes a "shift to the middle" (increase in intermediate cells). * **Clinical Use:** Though largely replaced by serum assays, it remains a classic exam topic for assessing primary amenorrhea or menopause.

Question 75: What are the characteristic hormonal changes observed in Polycystic Ovary Syndrome (PCOS)?

A. Low Progesterone
B. Normal LH, FSH, and Estradiol
C. High LH, low FSH, and low Estradiol (Correct Answer)
D. Low LH, FSH, and Estradiol

Explanation: ### Explanation **1. Why Option C is Correct (The Pathophysiology):** In PCOS, the fundamental endocrine derangement is an **increased frequency of GnRH pulses**, which preferentially stimulates the pituitary to produce **High LH**. This LH excess acts on the ovarian theca cells to produce excess androgens. * **Low/Low-Normal FSH:** The high levels of androgens are peripherally converted to **Estrone (E1)** in adipose tissue. This chronic estrogenic state exerts negative feedback on the pituitary, suppressing FSH. * **Low Estradiol (E2):** Because FSH is low, follicular recruitment is arrested, and the granulosa cells cannot efficiently aromatize androgens into Estradiol. Thus, while "total estrogen" (Estrone) is high, the potent **Estradiol (E2) remains low or at the lower limit of normal.** **2. Why Other Options are Incorrect:** * **Option A (Low Progesterone):** While progesterone is indeed low due to anovulation, it is a *consequence* of the hormonal milieu rather than the primary diagnostic hormonal profile used to characterize PCOS in exams. * **Option B & D:** These do not reflect the classic **LH:FSH ratio (usually >2:1 or 3:1)** seen in PCOS. Normal or low LH/FSH levels would suggest either a normal cycle or hypogonadotropic hypogonadism, respectively. **3. NEET-PG High-Yield Pearls:** * **The "Gold Standard" Ratio:** Look for an **LH:FSH ratio > 2:1**. * **Hyperinsulinemia:** Insulin acts synergistically with LH to increase androgen production and decreases **SHBG (Sex Hormone Binding Globulin)**, leading to more free (active) testosterone. * **Rotterdam Criteria:** Diagnosis requires 2 out of 3: (1) Clinical/Biochemical Hyperandrogenism, (2) Oligo/Anovulation, (3) Polycystic ovaries on USG. * **Estrone (E1) vs. Estradiol (E2):** Remember, PCOS is a state of **Hyperestronemia** (due to peripheral conversion) but not necessarily high Estradiol.

Question 76: What is true about Polycystic Ovarian Disease (PCOD)?

A. Luteinizing Hormone (LH) & Follicle-Stimulating Hormone (FSH) Ratio > 1:2
B. FSH & LH Ratio > 2:1
C. LH & FSH Ratio 1:1
D. Hyperinsulinemia (Correct Answer)

Explanation: **Explanation:** **Polycystic Ovarian Syndrome (PCOS/PCOD)** is a complex endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. **Why Hyperinsulinemia is Correct:** Hyperinsulinemia (and insulin resistance) is a central pathophysiological feature of PCOS, occurring in approximately 50–70% of cases. High levels of insulin act synergistically with **Luteinizing Hormone (LH)** to stimulate the **Theca cells** of the ovary, leading to increased androgen production. Furthermore, insulin suppresses the hepatic synthesis of **Sex Hormone Binding Globulin (SHBG)**, which increases the concentration of free (active) testosterone in the blood. **Analysis of Incorrect Options:** * **Options A, B, & C:** In PCOS, there is typically an **increased LH:FSH ratio**, classically cited as **> 2:1 or 3:1**. This occurs because of an increased frequency of GnRH pulses, which favors LH secretion over FSH. * Option A (LH:FSH > 1:2) and Option B (FSH:LH > 2:1) describe a state where FSH is higher than LH, which is the opposite of the PCOS profile. * Option C (1:1 ratio) is considered normal and not diagnostic of the pathology. **NEET-PG High-Yield Pearls:** * **Rotterdam Criteria (2 out of 3):** 1. Clinical/biochemical hyperandrogenism; 2. Oligo/anovulation; 3. Polycystic ovaries on ultrasound (≥12 follicles or volume >10ml). * **Gold Standard Investigation:** Transvaginal Ultrasound (TVS) showing a "String of Pearls" appearance. * **Biochemical Marker:** Increased **Anti-Müllerian Hormone (AMH)** levels are frequently seen due to the high number of small antral follicles. * **Clinical Sign:** **Acanthosis Nigricans** is a high-yield cutaneous marker of underlying hyperinsulinemia.

Question 77: In Polycystic Ovary Syndrome (PCOS), increased estrone levels are derived from which precursor?

A. Testosterone
B. Androstenedione (Correct Answer)
C. Dehydroepiandrosterone
D. Gonadotropin-releasing hormone (GnRH)

Explanation: **Explanation:** In Polycystic Ovary Syndrome (PCOS), the characteristic hormonal imbalance involves elevated androgens and a state of "unopposed estrogen." The primary source of this estrogen is the **peripheral aromatization** of androgens in adipose tissue. **Why Androstenedione is correct:** In PCOS, the ovaries (and to a lesser extent, the adrenals) overproduce **Androstenedione**. This precursor is converted into **Estrone (E1)** via the enzyme **aromatase**, primarily within peripheral fat cells. Unlike the cyclic production of Estradiol (E2) in a normal menstrual cycle, the chronic elevation of Estrone in PCOS provides constant positive feedback to the pituitary for LH secretion and negative feedback for FSH, contributing to the characteristic high LH:FSH ratio and chronic anovulation. **Analysis of Incorrect Options:** * **Testosterone:** While testosterone is elevated in PCOS, its peripheral aromatization primarily yields **Estradiol (E2)**, not Estrone. * **Dehydroepiandrosterone (DHEA):** DHEA is an upstream weak androgen. While it can eventually be converted to androstenedione, it is not the immediate precursor to estrone. * **GnRH:** This is a peptide hormone produced by the hypothalamus that regulates the release of LH and FSH; it is not a steroid precursor for estrogen. **High-Yield Clinical Pearls for NEET-PG:** * **The "PCOS Estrogen":** Remember that **Estrone (E1)** is the predominant estrogen in PCOS (and menopause), whereas **Estradiol (E2)** is the predominant estrogen in reproductive-age women. * **Endometrial Risk:** Chronic high levels of Estrone lead to endometrial hyperplasia, significantly increasing the risk of **Endometrial Carcinoma**. * **The Vicious Cycle:** Increased insulin (Hyperinsulinemia) decreases **Sex Hormone Binding Globulin (SHBG)**, further increasing the levels of free (active) androgens available for conversion to estrone.

Question 78: Which of the following are true about Stein-Leventhal syndrome?

A. Oligomenorrhea and amenorrhea
B. Seen in post-menopausal women (Correct Answer)
C. Numerous cysts in ovary
D. Theca cell hypertrophy

Explanation: **Stein-Leventhal Syndrome**, now more commonly known as **Polycystic Ovary Syndrome (PCOS)**, is a classic endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology. ### **Explanation of Options** * **Correct Answer (B): Seen in post-menopausal women.** The question asks which of the following is **TRUE**; however, in the context of standard medical examinations, this option is often used as a "distractor" or the "except" choice. Stein-Leventhal syndrome is a disease of the **reproductive age group** (typically 15–45 years). It does **not** develop in post-menopausal women, as the syndrome is driven by active (though deranged) hypothalamic-pituitary-ovarian axis function. *(Note: If the question asks for the "False" statement, B is the answer. If the question asks for "True" statements, A, C, and D are all classically correct features of the syndrome.)* * **Option A: Oligomenorrhea and amenorrhea.** This is a hallmark clinical feature. Chronic anovulation leads to irregular cycles (fewer than 9 periods a year) or a total absence of menstruation. * **Option C: Numerous cysts in ovary.** The "String of Pearls" appearance (12 or more follicles measuring 2–9 mm) is the classic radiological finding on ultrasound, representing arrested follicular development. * **Option D: Theca cell hypertrophy.** High levels of Luteinizing Hormone (LH) stimulate the ovarian theca cells, leading to hyperplasia and increased androgen production (androstenedione), which is a core pathophysiological mechanism of the disease. ### **NEET-PG High-Yield Pearls** * **Rotterdam Criteria (2 of 3):** 1. Clinical/Biochemical Hyperandrogenism; 2. Oligo/Anovulation; 3. Polycystic ovaries on USG. * **LH:FSH Ratio:** Classically elevated (>2:1 or 3:1). * **Gold Standard for Insulin Resistance:** Hyperinsulinemic-euglycemic clamp. * **Associated Risks:** Endometrial carcinoma (due to unopposed estrogen), Type 2 Diabetes, and Metabolic Syndrome. * **Treatment of Choice:** Weight loss (first-line); Combined Oral Contraceptive Pills (for cycle regularity); Clomiphene citrate/Letrozole (for infertility).

Question 79: Ovarian senescence is described by all of the following except:

A. Begins in utero within the embryonic ovary.
B. More rapid in the late 30s and early 40s.
C. Follicular activation is dependent on pituitary stimulation. (Correct Answer)
D. Programmed oocyte atresia.

Explanation: **Explanation:** Ovarian senescence refers to the progressive decline in the quantity and quality of the oocyte pool, ultimately leading to menopause. **Why Option C is the correct answer (The False Statement):** Initial follicular activation (the transition from primordial to primary follicle) is **gonadotropin-independent**. This process is regulated by local intra-ovarian growth factors (e.g., AMH, GDF-9, BMP-15) and occurs continuously regardless of the presence of FSH or LH. Pituitary stimulation (FSH) only becomes essential during the later stages of follicular development (antral stage) to prevent atresia and promote ovulation. **Analysis of Incorrect Options:** * **Option A:** True. Ovarian senescence begins in utero. The peak number of germ cells (6–7 million) is reached at 20 weeks of gestation, after which numbers decline via apoptosis before the female is even born. * **Option B:** True. The rate of follicular depletion is not linear; it accelerates significantly once the total follicle count drops below approximately 25,000, typically occurring in the late 30s or early 40s. * **Option C:** True. The primary mechanism of oocyte loss is programmed cell death (apoptosis/atresia), which occurs throughout a woman’s life, independent of pregnancy or contraceptive use. **High-Yield Clinical Pearls for NEET-PG:** * **Total Oocytes:** 6–7 million (20 weeks gestation) → 1–2 million (Birth) → 300,000–400,000 (Puberty) → <1,000 (Menopause). * **Best Marker of Ovarian Reserve:** Anti-Müllerian Hormone (AMH) is the most sensitive biochemical marker as it is produced by pre-antral follicles and is cycle-independent. * **Antral Follicle Count (AFC):** Measured via TVS; it is the best radiological marker for ovarian reserve. * **FSH Levels:** An FSH >40 IU/L on two occasions (1 month apart) is diagnostic of menopause.

Question 80: All of the following are used in the management of hirsutism except?

A. Spironolactone
B. GnRH
C. Danazol (Correct Answer)
D. OCPs

Explanation: **Explanation:** The management of hirsutism focuses on reducing circulating androgens or blocking their action at the hair follicle. **Why Danazol is the correct answer (The "Except"):** Danazol is a synthetic steroid and an **isoxazole derivative of ethisterone**. It is primarily used in the treatment of endometriosis and hereditary angioedema. Crucially, Danazol has **strong androgenic properties** and can cause side effects such as weight gain, acne, and **hirsutism** itself. Therefore, it is contraindicated in the management of hirsutism as it would exacerbate the condition. **Analysis of other options:** * **Spironolactone:** This is a potassium-sparing diuretic that acts as a potent **androgen receptor antagonist** and inhibits 5-alpha reductase. It is a first-line agent for idiopathic hirsutism. * **OCPs (Oral Contraceptive Pills):** These are the first-line treatment for PCOS-related hirsutism. They work by suppressing LH (decreasing ovarian androgen production) and increasing **Sex Hormone Binding Globulin (SHBG)**, which lowers free testosterone levels. * **GnRH Agonists:** These are used in severe cases or hyperthecosis. By causing pituitary desensitization, they lead to a profound decrease in ovarian steroidogenesis. **NEET-PG High-Yield Pearls:** * **First-line drug for PCOS-related hirsutism:** OCPs. * **Most common cause of hirsutism:** PCOS (Polycystic Ovary Syndrome). * **Ferriman-Gallwey Score:** Used to clinically quantify hirsutism (Score ≥8 is significant). * **Finasteride:** A 5-alpha reductase inhibitor also used in treatment. * **Eflornithine:** A topical cream used to inhibit hair growth by blocking ornithine decarboxylase.

Practice by Chapter

Hypothalamic-Pituitary-Ovarian Axis

Practice Questions

Disorders of Puberty

Practice Questions

Hirsutism and Virilization

Practice Questions

Primary Ovarian Insufficiency

Practice Questions

Hyperprolactinemia

Practice Questions

Hyperandrogenism

Practice Questions

Metabolic Dysfunction in PCOS

Practice Questions

Neuroendocrine Disorders and Reproduction

Practice Questions

Hormonal Evaluation and Testing

Practice Questions

Ovulation Induction

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free